Charles River Announces Extension of Integrated Discovery Program with Genentech
October 11 2016 - 8:00AM
Business Wire
Charles River Laboratories International, Inc. (NYSE: CRL) today
announced that it has extended its longstanding integrated drug
discovery alliance with Genentech, a member of the Roche Group.
“We are proud to work with Genentech to identify early-stage
molecules that will ultimately result in innovative treatments for
patients,” said John Montana, Executive Director, Integrated Drug
Discovery at Charles River. “Our long-term collaboration with
Genentech has been mutually beneficial for both companies. As our
teams have demonstrated, when biotechs and CROs work together, they
have the ability to enhance innovations in early discovery
research.”
Through this alliance, Charles River provides Genentech early
discovery services, including medicinal chemistry, in vitro and in
vivo biology, structural biology, and computer-aided drug design,
to help identify promising candidates for preclinical
development.
Charles River and Genentech have engaged in an ongoing program
since 2005, with the latest extension providing a three-year
continuation. The program began with a single project involving
medicinal chemistry, and has evolved over the past 11 years to a
multi-disciplinary collaboration drawing on Charles River’s leading
researchers in chemistry, biology and pharmacology.
About Charles River
Charles River provides essential products and services to help
pharmaceutical and biotechnology companies, government agencies and
leading academic institutions around the globe accelerate their
research and drug development efforts. Our dedicated employees are
focused on providing clients with exactly what they need to improve
and expedite the discovery, early-stage development and safe
manufacture of new therapies for the patients who need them. To
learn more about our unique portfolio and breadth of services,
visit www.criver.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161011005232/en/
Charles River Laboratories International, Inc.Investor
Contact:Susan E. Hardy, 781-222-6190Corporate Vice President,
Investor Relationssusan.hardy@crl.comorMedia Contact:Amy
Cianciaruso, 781-222-6168Corporate Vice President, Public
Relationsamy.cianciaruso@crl.com
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From Apr 2023 to Apr 2024